Year |
Citation |
Score |
2016 |
Garg G, Zhao H, Blagg BS. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors. Bioorganic & Medicinal Chemistry. PMID 27914946 DOI: 10.1016/J.Bmc.2016.11.030 |
0.406 |
|
2016 |
Hall J, Seedarala S, Zhao H, Garg G, Ghosh S, Blagg BS. Novobiocin Analogs That Inhibit the MAPK Pathway. Journal of Medicinal Chemistry. PMID 26745854 DOI: 10.1021/Acs.Jmedchem.5B01354 |
0.399 |
|
2015 |
White PT, Subramanian C, Zhu Q, Zhang H, Zhao H, Gallagher R, Timmermann BN, Blagg BS, Cohen MS. Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery. PMID 26542767 DOI: 10.1016/J.Surg.2015.07.050 |
0.307 |
|
2015 |
Liu W, Vielhauer GA, Holzbeierlein JM, Zhao H, Ghosh S, Brown D, Lee E, Blagg BS. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells. Molecular Pharmacology. 88: 121-30. PMID 25939977 DOI: 10.1124/Mol.114.097303 |
0.344 |
|
2015 |
Garg G, Zhao H, Blagg BS. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors. Acs Medicinal Chemistry Letters. 6: 204-9. PMID 25699150 DOI: 10.1021/Ml5004475 |
0.395 |
|
2015 |
Zhao H, Garg G, Zhao J, Moroni E, Girgis A, Franco LS, Singh S, Colombo G, Blagg BS. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. European Journal of Medicinal Chemistry. 89: 442-66. PMID 25462258 DOI: 10.1016/J.Ejmech.2014.10.034 |
0.404 |
|
2014 |
Zhao J, Zhao H, Hall JA, Brown D, Brandes E, Bazzill J, Grogan PT, Subramanian C, Vielhauer G, Cohen MS, Blagg BS. Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm. 5: 1317-1323. PMID 25328661 DOI: 10.1039/C4Md00102H |
0.39 |
|
2014 |
Zhao H, Anyika M, Girgis A, Blagg BS. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 24: 3633-7. PMID 24953820 DOI: 10.1016/J.Bmcl.2014.05.020 |
0.398 |
|
2014 |
Zhao H, Moroni E, Colombo G, Blagg BS. Identification of a new scaffold for hsp90 C-terminal inhibition. Acs Medicinal Chemistry Letters. 5: 84-8. PMID 24900777 DOI: 10.1021/Ml400404S |
0.393 |
|
2014 |
Ma J, Farmer KL, Pan P, Urban MJ, Zhao H, Blagg BS, Dobrowsky RT. Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. The Journal of Pharmacology and Experimental Therapeutics. 348: 281-92. PMID 24263156 DOI: 10.1124/Jpet.113.210435 |
0.331 |
|
2013 |
Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay and Drug Development Technologies. 11: 478-88. PMID 24127661 DOI: 10.1089/Adt.2012.498 |
0.373 |
|
2013 |
Zhao H, Blagg BS. Novobiocin analogues with second-generation noviose surrogates. Bioorganic & Medicinal Chemistry Letters. 23: 552-7. PMID 23234644 DOI: 10.1016/J.Bmcl.2012.11.022 |
0.397 |
|
2012 |
Zhao H, Moroni E, Yan B, Colombo G, Blagg BS. 3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. Acs Medicinal Chemistry Letters. 4: 57-62. PMID 23606927 DOI: 10.1021/Ml300275G |
0.368 |
|
2012 |
Zhao H, Yan B, Peterson LB, Blagg BS. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. Acs Medicinal Chemistry Letters. 3: 327-331. PMID 23316269 DOI: 10.1021/Ml300018E |
0.353 |
|
2012 |
Li C, Ma J, Zhao H, Blagg BS, Dobrowsky RT. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. Asn Neuro. 4: e00102. PMID 23240583 DOI: 10.1042/20120047 |
0.34 |
|
2012 |
Urban MJ, Pan P, Farmer KL, Zhao H, Blagg BS, Dobrowsky RT. Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Experimental Neurology. 235: 388-96. PMID 22465570 DOI: 10.1016/J.Expneurol.2012.03.005 |
0.352 |
|
2012 |
Zhang L, Zhao H, Blagg BS, Dobrowsky RT. C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. Journal of Proteome Research. 11: 2581-93. PMID 22413817 DOI: 10.1021/Pr300056M |
0.413 |
|
2012 |
Cohen SM, Mukerji R, Samadi AK, Zhang X, Zhao H, Blagg BS, Cohen MS. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Annals of Surgical Oncology. 19: S483-90. PMID 21837531 DOI: 10.1245/S10434-011-1971-1 |
0.359 |
|
2012 |
Cohen SM, Mukerji R, Samadi AK, Zhang X, Zhao H, Blagg BSJ, Cohen MS. Erratum to: Novel C-terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents Annals of Surgical Oncology. 19: 1720-1720. DOI: 10.1245/S10434-012-2280-Z |
0.337 |
|
2011 |
Kusuma BR, Peterson LB, Zhao H, Vielhauer G, Holzbeierlein J, Blagg BS. Targeting the heat shock protein 90 dimer with dimeric inhibitors. Journal of Medicinal Chemistry. 54: 6234-53. PMID 21861487 DOI: 10.1021/Jm200553W |
0.325 |
|
2011 |
Zhao H, Donnelly AC, Kusuma BR, Brandt GE, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BS. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. Journal of Medicinal Chemistry. 54: 3839-53. PMID 21553822 DOI: 10.1021/Jm200148P |
0.381 |
|
2011 |
Zhao H, Brandt GE, Galam L, Matts RL, Blagg BS. Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorganic & Medicinal Chemistry Letters. 21: 2659-64. PMID 21273068 DOI: 10.1016/J.Bmcl.2010.12.088 |
0.316 |
|
2010 |
Zhao H, Kusuma BR, Blagg BS. Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity. Acs Medicinal Chemistry Letters. 1: 311-315. PMID 21904660 DOI: 10.1021/Ml100070R |
0.41 |
|
2010 |
Donnelly AC, Zhao H, Reddy Kusuma B, Blagg BSJ. Cytotoxic sugar analogues of an optimized novobiocin scaffold Medchemcomm. 1: 165-170. DOI: 10.1039/C0Md00063A |
0.389 |
|
2008 |
Hua DH, Zhao H, Battina SK, Lou K, Jimenez AL, Desper J, Perchellet EM, Perchellet JP, Chiang PK. Total syntheses of (+/-)-ovalicin, C4(S *)-isomer, and its C5-analogs and anti-trypanosomal activities. Bioorganic & Medicinal Chemistry. 16: 5232-46. PMID 18356059 DOI: 10.1016/J.Bmc.2008.03.009 |
0.687 |
|
2007 |
Perchellet EM, Wang Y, Lou K, Zhao H, Battina SK, Hua DH, Perchellet JP. Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition. Anticancer Research. 27: 3259-71. PMID 17970069 |
0.754 |
|
2007 |
Perchellet EM, Wang Y, Lou K, Zhao H, Battina SK, Hua DH, Perchellet JP. Novel substituted 1,4-anthracenediones with antitumor activity directly induce permeability transition in isolated mitochondria. International Journal of Oncology. 31: 1231-41. PMID 17912452 DOI: 10.3892/Ijo.31.5.1231 |
0.749 |
|
2006 |
Hua DH, Lou K, Battina SK, Zhao H, Perchellet EM, Wang Y, Perchellet JP. Syntheses, molecular targets and antitumor activities of novel triptycene bisquinones and 1,4-anthracenedione analogs. Anti-Cancer Agents in Medicinal Chemistry. 6: 303-18. PMID 16842233 DOI: 10.2174/187152006777698141 |
0.744 |
|
2006 |
Wang Y, Perchellet EM, Ward MM, Lou K, Zhao H, Battina SK, Wiredu B, Hua DH, Perchellet JP. Antitumor triptycene analogs induce a rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria. International Journal of Oncology. 28: 161-72. PMID 16327993 DOI: 10.3892/Ijo.28.1.161 |
0.686 |
|
Show low-probability matches. |